Aarti Industries Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nj6r3ke984fg8c7l1i85gzoe.pdf

Key Takeaways


Demand Environment

Rajendra Gogri: "In the Dyestuff sector - you might have seen in the news also, that there is a significant slowdown in the Indian dyestuff market and it is very, very severe. Hopefully, things should start getting better in the next few months."

Long-Term Contracts & Volume Ramp-Up

Rajendra Gogri: "Overall, the way it is structured, even the top line may be less, but at the EBITDA level, there will not be much impact linked to the capacity utilization."

Nitric Acid Strategy & CAPEX

Rajendra Gogri: "If you're backward integrated then you are in-line with everybody because everybody has to source ammonia at global prices."

Margins & Operating Leverage

Rajendra Gogri: "In the Chemicals segment, we expect a substantial jump in EBITDA in FY'24 and FY'25. Then the new project will start kicking in from FY'25 onwards."

Pharma Business & Demerger


Guidance & Commitments

CommitmentSpecificsTimeline
First long-term contract utilizationReach 70–80% utilizationBy FY24 end
Second long-term contract utilizationReach 70–80% plus utilizationBy FY24
Third long-term contract and NCB expansionCommissioned and contributing to revenuesFrom FY24
Concentrated nitric acid plant225–250 TPD plant commissionedQ4 FY24
Fixed cost absorptionSubstantial part of fixed cost built in; no major increase thereafterBy FY23 end
Chemicals segment EBITDASubstantial jump as volumes rampFY24 and FY25
Guidance revision decisionReview full-year guidance after assessing Q2 demandAfter Q2
Debt-to-equity ceilingTarget 0.7–0.9x on the higher side if nitric acid investment proceedsOngoing
Combined CAPEX~₹3,000 croreFY23 and FY24 combined

Key Metrics

MetricQ1 FY23
Revenue₹2,173 cr, up 45% YoY
EBITDA₹369 cr, up 18% YoY; normalized for ₹32 cr shortfall income in Q1 FY22, growth closer to 30%
Profit after tax₹189 cr, up 15% YoY
Mark-to-market forex impact on PBT₹30 cr negative impact, from ECB depreciation vs USD
Specialty Chemicals revenue₹1,766 cr, up 44% YoY
Specialty Chemicals EBIT₹250 cr, up 8% YoY; normalized for shortfall income, growth about 25%
Pharma revenue₹407 cr, up 48% YoY
Pharma EBIT₹76 cr, up 46% YoY
Revenue growth split~25% from raw material price increases, ~15–20% from volume growth
Export share46%, up from below 40% in Q4 FY22
CAPEX incurred in Q1Over ₹200 cr
Planned CAPEX over FY23–FY24Close to ₹3,000 cr
First long-term contract utilization~25% in Q1; full-year FY23 expected 30–40%, H2 around 50%
Second long-term contract utilization~40% in Q1
Nitrochlorobenzene production20,515 MT for the quarter
Nitrotoluene production5,252 MT for the quarter
PDA volumes~370 tons per month
Value-added products share in Specialty Chemicals74%
USFDA audit at Dombivli API unit2 observations under Form 483